left-arrow right-arrow pinterest facebook google_plus linkedin

Eli Lilly I5B-MC-JGDP

Status:

Recruiting | Phase II

Official Title:

A Phase II (Randomized, Double-Blinded) Study Evaluating Nab-Paclitaxel and Gemcitabine with or without Olaratumab in the Treatment of First-Line Metastatic Pancreatic Cancer

Study Purpose:

The purpose is to study the safety of olaratumab in combination with nab-paclitaxel and gemcitabine, or any side effects you might have when you receive the combination treatment. Whether olaratumab in combination with nab-paclitaxel and gemcitabine can help patients with a certain type of pancreatic cancer that has spread to other organs.

Interventions:

  • Group 1: Olaratumab (study agent) in combination with nab-paclitaxel and gemcitabine
  • Group 2: Placebo in combination with nab-paclitaxel and gemcitabine

Patients will receive the study treatment until disease progression or a criterion for discontinuation is met.

Key Participation Requirements:

Gender:

Male or Female

Age:

19 years and older

Diagnosis:

Stage IV metastatic pancreatic cancer

Eligibility:

Metastatic Pancreatic cancer

Patients may not have been treated with nab-paclitaxel

Patients must sign an approved informed consent and authorization permitting release of personal health information.

Methodist Health System Trial Code:

Eli Lilly I5B-MC-JGDP

For more information, visit the U.S. National Library of Medicine clinical trial database.

To learn more about this clinical trial please contact us today!